纤溶酶治疗急性脑梗死的临床疗效观察

Fibrinolytic treatment of acute cerebral infarction efficacy

目的:观察纤溶酶治疗急性脑梗死(ACI)的疗效和不良反应。方法:将82例急性脑梗死患者按住院顺序随机分为对照组和治疗组进行对比研究,对照组采用常规内科治疗,治疗组在此基础上加用纤溶酶静滴,每天静滴1次,连续静滴10天;分别对两组患者进行治疗前、治疗后11天的神经功能缺损评分及临床疗效评估和血液流变学比较,观察药物不良反应。结果:两组患者经过治疗后,神经功能缺损较治疗前均有显著改善(P<0.01),治疗组与对照组比较有显著性差异(P<0.01)。治疗后临床疗效评价显示,治疗组总有效率为92.8%,对照组总有效率62.5%,二者有明显差异(P<0.01)。比较两组的血液流变学检查结果,治疗组要明显优于对照组,有统计学意义(P<0.05)。两组均未发现药物不良反应和毒副作用。结论:纤溶酶作为治疗急性脑梗死的常用药物,具有安全有效且价格适中等优点,值得在基层医院推广使用。

Objective：Fibrinolytic treatment of acute cerebral infarction（ACI） of the efficacy and adverse reactions.Method：of 82 hospitalized patients with acute cerebral infarction by randomly divided into control and treatment groups were compared,the control group with conventional medical treatment,the treatment group based on the use of this plasminogen infusion,day 1,once every 10 days;each of the two groups before treatment and 11 days after the neurological deficit score and clinical evaluation and blood rheology compared to observe the adverse drug reactions.Results：After treatment of neurological deficit before treatment were significantly improved（P0.01）,the treatment group compared with the control group there was significant difference（P0.01）,after treatment,clinical evaluation of the treatment group,the total efficiency 92.8% 62.5% compared with the control group were significantly different（P0.01）.Two sets of blood rheology test results,treatment group was significantly better than the control group,was statistically significant（P0.05）.Two groups were not found adverse drug reactions and side effects.Conclusion：plasmin as a treatment for acute cerebral infarction,safe,effective and affordable,it is used in primary hospitals.